STOCK TITAN

DNA X, Inc. SEC Filings

SONM NASDAQ

Welcome to our dedicated page for DNA X SEC filings (Ticker: SONM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DNA X's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.

Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DNA X's regulatory disclosures and financial reporting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Schedule 13G/A Amendment No. 3 overview:

Investor Laurence W. Lytton has disclosed beneficial ownership of 1,200,000 Sonim Technologies (SONM) shares as of 30-Jun-2025. The stake comprises 800,000 common shares and warrants for 400,000 additional shares, subject to a 19.99 % ownership cap, and equals 11.2 % of the company’s 10,338,905 shares outstanding reported on 18-Jun-2025. All voting and dispositive powers are shared; the filer holds no sole authority.

The filing is made under Rule 13d-1(c), indicating a passive investment rather than an activist position. The certification states the securities were not acquired to influence control. The statement is signed and dated 02-Jul-2025.

Key data

  • Beneficial owner: Laurence W. Lytton (U.S.)
  • Common shares: 800,000
  • Warrants: 400,000
  • Total beneficial ownership: 1.2 million shares
  • Ownership percentage: 11.2 %
  • Sole voting/dispositive power: 0
  • Shared voting/dispositive power: 1.2 million

No other group members or subsidiaries are identified.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.69%
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.69%
Tags
proxy
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.69%
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-44.26%
Tags
prospectus
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-44.26%
Tags
amendment
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-44.26%
Tags
other
Rhea-AI Summary

On 30 June 2025, a Form 4 was filed reporting insider activity at Sonim Technologies (SONM). The filing shows that Laurence W. Lytton —identified as a 10 % owner (and indicated as a director) —sold his entire direct position in two open-market transactions coded “S.”

  • 26 Jun 2025: 466,402 shares sold at a weighted-average price of $1.50 (price range $1.28-$1.75), leaving 400,514 shares directly held.
  • 30 Jun 2025: 400,514 shares sold at a weighted-average price of $1.39 (price range $1.30-$1.47), reducing direct ownership to 0 shares.

In total, 866,916 shares were disposed of during the four-day window.

Lytton continues to have indirect exposure to 800,000 shares held by the Lytton-Kambara Foundation. He disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.

No derivative securities were involved, and no purchases were reported. The complete exit from a direct holding by a 10 % owner is often viewed by investors as a potentially bearish signal, although the remaining foundation stake maintains some alignment of interests.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.08%
Tags
insider

FAQ

How many DNA X (SONM) SEC filings are available on StockTitan?

StockTitan tracks 83 SEC filings for DNA X (SONM), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for DNA X (SONM)?

The most recent SEC filing for DNA X (SONM) was filed on July 7, 2025.